Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.0802-0.0198 (-0.64%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1000
Open3.0500
Bid2.9000 x 100
Ask3.4200 x 1100
Day's range2.9200 - 3.0829
52-week range1.7500 - 9.1200
Volume987
Avg. volume2,868
Market cap8.348M
Beta (5Y monthly)1.77
PE ratio (TTM)N/A
EPS (TTM)-5.3900
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    12 Best Biotech Penny Stocks to Invest In

    In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]

  • GlobeNewswire

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for

  • GlobeNewswire

    Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

    - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G